The European Joint Programming Initiative on Neurodegenerative Disease Research (JPND) Organises Its International Scientific Meeting
26.11.2019 20:37:00 EET | Business Wire | Press release
To disseminate up-to-date research achievements from 51 completed JPND-supported projects3 to relevant stakeholders, liaise, exchange knowledge and network, projects coordinators and their research consortiums, leading researchers and stakeholders will meet at the Royal Flemish Academy of Belgium for Sciences and the Arts in Brussels, Belgium, for a two-day symposium from 27 November to 28 November, 2019. This promises to provide a unique platform and opportunity for researchers to find out about one another’s work, communicate their latest research findings from their completed projects, build new relationships and enhance existing ones.
JPND Chair, Professor Philippe Amouyel says: “As the first and largest global collaborative research initiative established to tackle the growing challenge posed by neurodegenerative diseases, JPND’s ultimate goal is to improve the scientific understanding of neurodegenerative diseases, provide innovative approaches for their prevention, diagnosis and treatment, and ensure that individuals receive optimal care and quality of life at all stages of their illness. This symposium aims to facilitate knowledge sharing and communication between the different research groups and to disseminate up-to-date research achievements to relevant stakeholders.”
Project topics to be presented will range from Alzheimer’s to Parkinson’s diseases to rarer diseases such as Huntington’s disease, Amyotrophic Lateral Sclerosis, Prion disease, Spinal Muscular Atrophy and Spinocerebellar Ataxia .
Apart from 12 scientific sessions chaired and moderated by leading researchers in the field of neurodegenerative disease, the symposium will also delve into major questions of research via four thematic workshops, namely: Patient and Public Involvement in Research, Interactions with Industry, Knowledge Dissemination and Data Sharing.
Note to Editors:
JPND is committed to aligning and building upon national programmes to increase impact and effectiveness of research and to identify common goals that would benefit from joint action.
- The origins and progression of neurodegenerative diseases
- Disease mechanisms and models
- Diagnosis, prognosis and disease definitions
- Developing therapies, preventive strategies and interventions
- Health and social care
JPND receives support from the European Commission.
Web: www.jpnd.eu
Twitter: @JPNDEurope
LinkedIn: https://www.linkedin.com/company/jpnd-joint-programme-neurodegenerative-disease-research
1
The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases.
2
In 2015, JPND launched a joint transnational co-funded call in partnership with the European Commission under the ERA-NET Co-fund scheme in three JPND priority areas: Longitudinal Cohort Approaches, Advanced Experimental Models and Risk and Protective Factors
3 Research projects supported by the JPND calls of 2011 to 2013 and the JPco-fuND call of 2015
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005698/en/
Contact information
Press
Name: Karin YEO
Mobile: +33 07 8227 2887
Email: karin.yeo@jpnd.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SuperElastic* Material Unveiled by Angelalign2.11.2026 19:46:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other treatments,“ said Fox Hu, CEO of Angel. MC-SE will be available globally
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 19:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise spanning consumer-facing businesses, healthcare, medtech and life sciences. As Galderma advances its ambition to become the undisputed dermatology powerhouse, spanni
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 16:35:00 EET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 16:00:00 EET | Press release
Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contributing. As AI accelerates campaign execution, the quality of each decision matters more.” Intelligence Pro combines four capabilities within Smartly’s platform: Reach Planner helps teams comp
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 16:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key Highlights Proven platform: medicalforce is used by more than 800 clinics*1 in Japan, primarily self-pay clinics, with a clinic retention rate of 99.2%*2. Joint AI development: Features co-developed by the two companies will enhance medicalforce and be progressively incorpo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
